Minakem Generic APIs Minakem Generic APIs

X
[{"orgOrder":0,"company":"McSAF","sponsor":"Axplora","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"McSAF and Novasep Announce Their Successful Collaboration To Produce A Next-generation Antibody-Drug Conjugate (ADC)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"FRANCE","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"}]

Find Clinical Drug Pipeline Developments & Deals by McSAF

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            Novasep has successfully optimized and scaled-up the process of Adcitmer® (monomethyl auristatin E-conjugated antibody), McSAF Inside® Oncology’s first-in-class proprietary ADC to treat neuroendocrine cancers.

            Lead Product(s): Monomethyl Auristatin E-Conjugated Antibody

            Therapeutic Area: Oncology Product Name: Adcitmer

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Axplora

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration November 18, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY